Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens

  • Vaccitech plc VACC announced an update to the interim analysis of safety and efficacy data from the HBV002 study evaluating ChAdOx1-HBV and MVA-HBV vaccines (VTP-300) in chronic HBV patients who are virally suppressed with oral anti-viral therapies.
  • In the VTP-300 monotherapy group, meaningful and durable reductions of HBsAg were seen in all three patients with baseline HBsAg under 50 IU/mL.
  • Related: Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial.
  • HBsAg is a hallmark of chronic hepatitis B virus (HBV) infection.
  • These three patients had 0.7, 0.7, and 1.4 log10 declines two months after the last VTP-300 and persisted in all three patients at their latest follow-up five or eight months after the last VTP-300.
  • For the first eight patients who received VTP-300 in combination with a single low dose of nivolumab at the time of the booster dose, the mean reduction in HBsAg was over 1 log10 at six months and persisted with a mean decline of 1.15 log10 at eight months after the last dose of VTP-300.
  • One patient developed a non-detectable HBsAg level, which continued eight months after the last dose of VTP-300.
  • Enrollment in the HBV002 study is complete, with 55 patients enrolled.
  • Updated interim analysis for all patients at the six-month follow-up timepoint is expected at the end of 2022.
  • Price Action: VACC shares are up 21.70% at $5.55 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!